Royal Bank Of Canada Chinook Therapeutics, Inc. Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $13,099 - $27,083	702 Added 14.44%	5,562 $213,000
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $68,379 - $85,116	-3,176 Reduced 39.52%	4,860 $112,000
Q4 2022 Feb 14, 2023	BUY	$18.63 - $27.35 $126,982 - $186,417	6,816 Added 558.69%	8,036 $210,000
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $17,037 - $22,739	973 Added 393.93%	1,220 $24,000
Q2 2022 Aug 15, 2022	SELL	$12.59 - $18.8 $28,088 - $41,942	-2,231 Reduced 90.03%	247 $4,000
Q1 2022 May 16, 2022	SELL	$12.02 - $16.69 $60,051 - $83,383	-4,996 Reduced 66.85%	2,478 $41,000
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $47,142 - $74,220	4,410 Added 143.93%	7,474 $122,000
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $10,143 - $13,106	882 Added 40.42%	3,064 $39,000
Q2 2021 Aug 16, 2021	BUY	$13.6 - $18.98 $29,675 - $41,414	2,182 New	2,182 $30,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.